Related Experiment Video
Updated: Jun 21, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Cyclophilin inhibitors
1Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA. gallay@scripps.edu
Clinics in Liver Disease
|July 25, 2009
Summary
New cyclophilin (Cyp) inhibitors show promise for treating chronic hepatitis C virus (HCV) infections. These agents offer a novel mechanism and potential for combination therapy, addressing limitations of current treatments.
Area of Science:
- Hepatology and Virology
- Drug Discovery and Development
Background:
- Chronic hepatitis C virus (HCV) infection remains a significant global health concern.
- Current pegylated interferon-alpha (pIFNa)/ribavirin (RBV) therapy has limited efficacy (approx. 50%) and significant side effects.
- Development of novel anti-HCV agents is urgently needed.
Purpose of the Study:
- To highlight the potential of cyclophilin (Cyp) inhibitors as a new class of anti-HCV drugs.
- To discuss the novel mechanism of action and efficacy of Cyp inhibitors.
- To evaluate Cyp inhibitors as candidates for combination therapies.
Main Methods:
- Review of recent clinical studies on cyclophilin (Cyp) inhibitors.
- Analysis of the mechanism of action and efficacy profiles of Cyp inhibitors.
- Assessment of the potential for combination therapy with existing and future HCV treatments.
Main Results:
- Cyclophilin (Cyp) inhibitors have demonstrated potent antiviral activity against HCV.
- These inhibitors possess a novel mechanism of action distinct from current therapies.
- Their efficacy profiles suggest suitability for combination treatment strategies.
Conclusions:
- Cyclophilin (Cyp) inhibitors represent a promising new therapeutic avenue for chronic hepatitis C virus (HCV) infection.
- Their novel mechanism and efficacy make them valuable candidates for combination therapies.
- Further development of Cyp inhibitors could significantly improve HCV treatment outcomes.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...